Drug Profile


Alternative Names: IV posaconazole; MK-5592; Noxafil; Posaconazole oral suspension; Posaconazole SP; Posaconazole tablet; Posanol; SCH 056592; SCH 56592; Spriafil

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; MSD China; Schering-Plough
  • Class Antifungals; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidiasis; Mycoses; Oropharyngeal candidiasis
  • Phase II Chagas disease

Most Recent Events

  • 01 Mar 2017 Merck terminates a phase I trial in Mycoses (In infants, In children, In adolescents) in Germany, Canada, USA, Italy, Netherlands, Greece based on preliminary analysis of pharmacokinetic data (PO) (NCT01716234) (EudraCT2007-004645-15)
  • 02 Nov 2016 Posaconazole receives Orphan Drug status for Aspergillosis in USA
  • 01 May 2016 Merck Sharp and Dohme completes a phase I pharmacokinetics trial for Mycoses in China (NCT02387983)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top